Abstract: Renal anemia is one of the common complications of chronic kidney disease (CKD), which has a profound impact on the prognosis of patients. The traditional treatment of renal anemia, such as the use of erythropoietin (EPO) and iron, is not ideal for some patients, and maybe accompanied by adverse reactions. Therefore, there is an urgent need to find new treatment options. Recent studies have revealed that ferroportin 1 (FPN1) plays a key role in the treatment of renal anemia. In this review, the regulatory mechanism of FPN1 in iron metabolism in renal anemia and the role of treatment strategies targeting FPN1 in the progress of renal anemia treatment are discussed in detail.

Key words: font-family:Inter, -apple-system, BlinkMacSystemFont, ", font-size:16px, background-color:#F9FAFB, ">ferroportin1, hypoxia?inducible factor, hepcidin, renal anemia